"Southlake Oncology, a Choice Cancer Care Treatment Center, located in the Southlake and Grapevine area, is a community-focused oncology practice that delivers exceptional care to North Texas cancer patients with a variety of cancer diagnoses and blood disorders. Like the other Choice Cancer Care facilities, we are an independent treatment center that is physician-owned. As such, we have been able to build treatment centers that are in line with our unique patient care model; facilities that are completely committed to providing integrated cancer therapies that speak to the health of the whole person. Whether you are facing breast cancer, prostate cancer, lung cancer, or any other malignancy, you will find the compassion and respect you"

During the past decade, Southlake Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Southlake Oncology" #1 collaborator was "United States Department of Defense" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Southlake Oncology" are "Breast Cancer" (2 trials), "Breast Neoplasms" (1 trials) and "Prostate Cancer" (1 trials). Many other conditions were trialed in "Southlake Oncology" in a lesser frequency.

Most popular intervention types in "Southlake Oncology" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ChemoFX Assay" (1 trials), "Docetaxel" (1 trials), "Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2" (1 trials), "Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2" (1 trials) and "Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2" (1 trials). Other intervention names were less common.

The vast majority of trials in "Southlake Oncology" are 2 trials for "Female" genders, 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Southlake Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Southlake Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Southlake Oncology, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".